Fiche publication
Date publication
janvier 2026
Journal
Crohn's & colitis 360
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine
Tous les auteurs :
Vuitton L, Fumery M, Foulley L, Habauzit C, Benkhalifa S, Buisson A
Lien Pubmed
Résumé
At the end of the past century, infliximab (IFX), the first-in-class biological therapy approved in inflammatory bowel disease (IBD), dramatically modified the therapeutic armamentarium. The recent development of subcutaneous (SC) formulations of IFX offers a promising alternative, with the potential to improve patient convenience, adherence, and overall outcomes. This review explores the clinical evidence supporting the initiation of SC IFX and the transition from intravenous (IV) to SC IFX.
Mots clés
Crohn’s disease, inflammatory bowel disease (IBD), infliximab, subcutaneous, ulcerative colitis
Référence
Crohns Colitis 360. 2026 01;8(1):otag010
